APA

Zhang Q., Lapalus M., Asselah T., Laouénan C., Moucari R., Martinot-Peignoux M., Bieche I., Estrabaud E., De Muynck S., Boyer N., Bedossa P., Vidaud M., Marcellin P. & Lada O. (20150126). IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. : Journal of viral hepatitis.

Chicago

Zhang Q, Lapalus M, Asselah T, Laouénan C, Moucari R, Martinot-Peignoux M, Bieche I, Estrabaud E, De Muynck S, Boyer N, Bedossa P, Vidaud M, Marcellin P and Lada O. 20150126. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. : Journal of viral hepatitis.

Harvard

Zhang Q., Lapalus M., Asselah T., Laouénan C., Moucari R., Martinot-Peignoux M., Bieche I., Estrabaud E., De Muynck S., Boyer N., Bedossa P., Vidaud M., Marcellin P. and Lada O. (20150126). IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. : Journal of viral hepatitis.

MLA

Zhang Q, Lapalus M, Asselah T, Laouénan C, Moucari R, Martinot-Peignoux M, Bieche I, Estrabaud E, De Muynck S, Boyer N, Bedossa P, Vidaud M, Marcellin P and Lada O. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. : Journal of viral hepatitis. 20150126.